Molnlycke Health Care, a Swedish medtech company specialising in wound care and wound management, announced on Thursday that it has entered into a research collaboration with Transdiagen (TDG), a UK-based precision medicine company that develops drugs and diagnostics for chronic wound healing and tissue regeneration.

The partners intend to use TDG's novel wound gene signatures to further explore Molnlycke products.

Emma Wright, Molnlycke EVP chief medical officer, said: "We are excited by our research collaboration with TDG allowing us to be at the forefront of advanced understanding of chronic wounds. This opens up a wealth of opportunities for future innovation in the under resourced and under prioritised area of wound care."

James Harding, Transdiagen CEO, added: "This collaboration will allow Molnlycke access to TDG's novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds."